Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix immunogenicity study in newly diagnosed pediatric leukemia
ACTRN12609000515291Phase 3Active, not recruiting
- Sponsor
- NHMRC Centre of Clinical Research Excellence in Childhood and Adolescent Immunisation
- Start
- Jun 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 10-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD) (2 arms), sponsored by NHMRC Centre of Clinical Research Excellence in Childhood and Adolescent Immunisation. Primary endpoint: Primary serologic response to 10vPCV. Started Jun 2009; status: active, not recruiting.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on ACTRN12609000515291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000515291.